Our data showed that TRAF2-KO, TRAF3-KO, and TRAF2/3-DKO lymphoma cells were more sensitive to AZD treatment alone or to combined treatment of AZD/DOX (Supplementary Fig. 8D, E). This evidence concerns the gene TRAF2 and lymphoma.